<<

. 9
( 9 .)



of first-line antiretroviral therapy with regimens including Pharmacokinetics of indinavir and low-dose ritonavir in children
nevirapine, efavirenz, or both drugs, plus stavudine and with HIV-1 infection. AIDS 14 (2000), 2209–19.
lamivudine, a randomised open-label trial, the 2NN Study. 90. Shearer, W. T., Quinn, T. C., LaRussa, P. et al. Viral load and
Lancet 363(9417) (2004), 1253–63. disease progression in infants infected with human
80. Sulkowski, M. S., Thomas, D. L., Mehta, S. H. et al. immunodeficiency virus type 1. New Engl. J. Med. 336 (1997),
Hepatotoxicity associated with nevirapine or efavirenz- 1337–42.
containing antiretroviral therapy: role of hepatitis C and B 91. McIntosh, K., Shevitz, A., Zaknun, D. et al. Age- and time
infections. Hepatology 35: 1 (2002), 182–9. related changes in extracellular viral load in children vertically
81. Saavedra, J., McCoig, C., Mallory, M. et al. Clinical experience infected by human immunodeficiency virus. Pediatr. Infect. Dis.
with triple nucleoside (NRTI) combination ZDV/3TC/abacavir J. 15 (1996), 1087–91.
(ABC) as initial therapy in HIV-infected children. In 41st 92. Marschner, I. C., Collier, A. C., Coombs, R.W. et al. Use of
Interscience Conference on Antimicrobial Agents and changes in plasma levels of human immunodeficiency virus type
Chemotherapy. September 22–25, (2001), Chicago, IL [Abstract 1 RNA to assess the clinical benefit of antiretroviral therapy. J.
1941]. Infect. Dis. 177 (1998), 40–7.
82. Wells, C. J., Sharland, M., Smith, C. J. et al. Triple nucleoside 93. Connors, M., Kovacs, J. A., Krevat, S. et al. HIV infection
analogue therapy with zidovudine (AZT), lamivudine (3TC), induces changes in CD4+ T-cell phenotype and depletions
and abacavir (ABC) in the paediatric HIV London South within the CD4+ T cell repertoire that are not immediately
Network (PHILS-NET) cohort. In XIV International AIDS restored by antiviral or immune-based therapies. Nat. Med. 3
Conference. July 7–12, (2002), Barcelona, Spain [Abstract (1997), 533– 40.
TuPeB4625].
94. Barnhart, H. X., Caldwell, M. B., Thomas, P. et al. Natural
83. Paediatric European Network for Treatment of AIDS (PENTA). history of human immunodeficiency virus disease in perinatally
Comparison of dual nucleoside analogue reverse transcriptase infected children: an analysis from the Pediatric Spectrum of
inhibitor regimens with and without nelfinavir in children with Disease Project. Pediatrics 97 (1996), 710–6.
HIV-1 who have not previously been treated: the PENTA 5
95. Durant, J., Clevenbergh, P., Halfon, P. et al. Drug-resistance
randomised trial. Lancet 359 (2002), 733–40.
genotyping in HIV-1 therapy: the VIRADAPT randomised
84. Kline, M.W., Brundage, R. C., Fletcher, C. V. et al. controlled trial. Lancet 353 (1999), 2195–9.
Combination therapy with saquinavir soft gelatin capsules in
96. Cohen, C. J., Hunt, S., Sension, M. et al. A randomized trial
children with human immunodeficiency virus infection. Pediatr.
assessing the impact of phenotypic resistance testing on
Infect. Dis. J. 20 (2001), 666–71.
antiretroviral therapy. AIDS 16 (2002), 579–88.
85. Grub, S., DeLora, P., Ludin, E. et al. Pharmacokinetics and
97. Cingolani, A., Antinori, A., Rizzo, M. G. et al. Usefulness of
pharmacodynamics of saquinavir in pediatric patients with
monitoring HIV drug resistance and adherence in individuals
human immunodeficiency virus infection. Clin. Pharmacol.
failing highly active antiretroviral therapy: a randomized study
Ther. 71 (2002), 122–30.
(ARGENTA). AIDS 16 (2002), 369–79.
86. Hoffmann, F., Notheis, G., Wintergerst, U. et al. Comparison of
98. Meynard, J.-L., Vray, M., Morand-Joubert, L. et al. Phenotypic
ritonavir plus saquinavir- and nelfinavir plus saquinavir
or genotypic resistance testing for choosing antitretroviral
containing regimens as salvage therapy in children with human
therapy after treatment failure: a randomized trial. AIDS 16
immunodeficiency virus type 1 infection. Pediatr. Infect. Dis. J.
(2002), 727–36.
19 (2000), 47–51.
99. Yeni, P. G., Hammer, S. M., Carpenter, C.C. J. et al.
87. Moyle, G. Use of HIV protease inhibitors as
Antiretroviral treatment for adult HIV infection in 2002: updated
pharmacoenhancers. AIDS Reader February (2001), 87–98.
recommendations of the International AIDS Society-USA Panel.
88. Church, J. A., Cunningham, C., Hughes, M. et al. Safety and J. Am. Med. Assoc. 288 (2002), 222–35.
antiretroviral activity of chronic subcutaneous administration of




- . . . .

<<

. 9
( 9 .)